MahaswetaGooptuMD

PubMed

• Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.
  Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, Juan Wu, Carrie L Kitko
  Journal of Clinical Oncology. 2025-01-03
• How I Treat AML relapse after allogeneic HCT.
  Mahasweta Gooptu, H Moses Murdock, Robert J Soiffer
  Blood. 2024-12-24
• Reply to: Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide-Based Mismatched Unrelated Donor Transplantation.
  Brian C Shaffer, Mahasweta Gooptu, Todd DeFor, Stephen R Spellman, Heather E Stefanski
  Journal of Clinical Oncology. 2024-11-06

Abstracts/Posters

• Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation
  Mahasweta Gooptu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leu...
  Mahasweta Gooptu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease
  Mahasweta Gooptu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patie...
  Mahasweta Gooptu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all